554 results on '"Baldus, Claudia D."'
Search Results
2. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
3. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
4. Prognostic impact of CEBPA mutational subgroups in adult AML
5. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
6. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
7. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
8. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma
9. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
10. FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
11. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
12. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
13. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
14. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
15. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
16. Overlapping features of therapy-related and de novo NPM1-mutated AML
17. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
18. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
19. Molekulare Diversität der akuten lymphoblastischen Leukämie: Innovationen in Diagnostik und Therapie
20. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
21. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
22. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
23. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
24. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
25. An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse
26. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
27. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
28. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
29. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
30. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study
31. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
32. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
33. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
34. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
35. Prognostic impact of CEBPA mutational subgroups in adult AML
36. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma
37. Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
38. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
39. In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
40. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
41. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
42. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
43. Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?
44. The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
45. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia
46. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia
47. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
48. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
49. Supplementary Figures from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
50. Table S4 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.